EXJADE

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug EXJADE contains one active pharmaceutical ingredient (API):

1
UNII V8G4MOF2V9 - DEFERASIROX
 

Deferasirox is an orally active chelator that is highly selective for iron (III). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Deferasirox promotes excretion of iron, primarily in the faeces.

 
Read more about Deferasirox

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 EXJADE Granules in sachet MPI, EU: SmPC European Medicines Agency (EU)
 EXJADE Dispersible tablet MPI, EU: SmPC European Medicines Agency (EU)
 EXJADE Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
V03AC03 Deferasirox V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AC Iron chelating agents
Discover more medicines within V03AC03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
BR Câmara de Regulação do Mercado de Medicamentos 526526801110217, 526526802117215, 526526803113213
CA Health Products and Food Branch 02287420, 02287439, 02287447
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 27.265-09-06
EE Ravimiamet 1258624, 1258635, 1258646, 1258657, 1258668, 1258679, 1410499, 1410501, 1410512, 1693795, 1713923, 1713934, 1713945, 1713956, 1713967, 1713978, 1713989, 1713990, 1714003, 1755817, 1755828, 1755839, 1777934
ES Centro de información online de medicamentos de la AEMPS 106356011, 106356017
FI Lääkealan turvallisuus- ja kehittämiskeskus 084182, 381794, 395077
FR Base de données publique des médicaments 63404789, 65539020, 67055858
GB Medicines & Healthcare Products Regulatory Agency 336219, 336222, 336225
HK Department of Health Drug Office 54547, 54548, 54549
IE Health Products Regulatory Authority 88687, 88688, 88689
IL מִשְׂרַד הַבְּרִיאוּת 4925, 4926, 4927
IT Agenzia del Farmaco 037421118, 037421144, 037421171
LT Valstybinė vaistų kontrolės tarnyba 1028091, 1028092, 1028093, 1028094, 1028095, 1028096, 1056579, 1056580, 1056581, 1076652, 1080007, 1080008, 1080009, 1080010, 1080011, 1080012, 1080013, 1080014, 1080015, 1084436, 1084437, 1084438
MX Comisión Federal para la Protección contra Riesgos Sanitarios 192M2006
NL Z-Index G-Standaard, PRK 137189, 137197, 137200, 81736, 81744, 81752
NZ Medicines and Medical Devices Safety Authority 12113, 12114, 12115
PL Rejestru Produktów Leczniczych 100135197, 100135375, 100136245, 100372402, 100372425, 100372431, 100397738, 100397744, 100397750
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W64440001, W64440002, W64440003, W64441001, W64441002, W64441003, W64442001, W64442002, W64442003, W64443001, W64443002, W64443003, W64444001, W64444002, W64444003
SG Health Sciences Authority 13393P, 13394P, 13395P
TN Direction de la Pharmacie et du Médicament 10283251H, 10283252H, 10283253H
TR İlaç ve Tıbbi Cihaz Kurumu 8699504070019, 8699504070026, 8699504070033
US FDA, National Drug Code 0078-0468, 0078-0469, 0078-0470
ZA Health Products Regulatory Authority A40/27/0266, A40/27/0267, A40/27/0268

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.